Outpatient COVID-19 Treatment for Generally Healthy Adults

Introduction to Treatment Guidelines

The American College of Physicians recommends nirmatrelvir/ritonavir as the first-line treatment for high-risk patients with mild-to-moderate COVID-19, initiated within 5 days of symptom onset 1, 2

High-risk features that warrant antiviral treatment include unvaccinated status, age ≥65 years, immunosuppression, multiple comorbidities (≥3), hematological disease, and radiographic evidence of pneumonia 1

Nirmatrelvir/ritonavir 300 mg/100 mg orally twice daily for 5 days is prescribed for high-risk patients, with a mandatory comprehensive medication review using a drug interaction checker before prescribing 1, 2
Treatment must be initiated within 5 days of symptom onset for effectiveness 1, 2

Nirmatrelvir/ritonavir reduces all-cause mortality and COVID-19-specific mortality 1
Real-world data shows 39% relative risk reduction in hospitalization and 61% relative risk reduction in death 2
Nirmatrelvir/ritonavir may reduce long COVID incidence by 25% 2

Molnupiravir is used only when nirmatrelvir/ritonavir is contraindicated or unavailable, and reduces all-cause mortality and time to recovery but is less effective than nirmatrelvir/ritonavir 1, 2

Symptomatic treatment only is provided for patients without high-risk features, including antipyretics for fever, adequate hydration, rest, and monitoring for clinical deterioration 1, 3, 4

The European Respiratory Society recommends against prescribing ivermectin, sotrovimab, azithromycin, systemic corticosteroids, hydroxychloroquine, lopinavir-ritonavir, and vitamin D supplementation for outpatient COVID-19 treatment 1, 4, 5

During treatment, monitor hepatic function if baseline liver abnormalities are present, ensure patient continues isolation per public health recommendations, and assess for hypersensitivity reactions 1, 2
Symptoms commonly persist into the fourth week of illness, with only 28.9% reporting complete resolution by week 4 1

Prescribing antivirals to low-risk patients without high-risk features exposes them to unnecessary drug interaction risks without meaningful benefit 2
Delaying treatment beyond 5 days of symptom onset significantly decreases effectiveness 1, 2
Failing to perform comprehensive drug interaction screening before prescribing nirmatrelvir/ritonavir can lead to life-threatening interactions 1, 2
Using hydroxychloroquine or ivermectin based on misinformation demonstrates no benefit 1, 5